UNSPSC 51144119: Etolorex

This classification denotes an anorexiant with the molecular formula C12H18ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 449NCX1P03, chemically known as 2-((p-chloro-alpha,alpha-dimethyl-phenethyl)amino)ethanol but more generally known as etolorex, which bears US NIH Compound Identifier 208943. European Medicines Agency schedules Etolorex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07327MIG.

UNSPSC 51144119 Etolorex is a Commodity code covering pharmaceutical products and related health-care goods procured by state and local health agencies, counties, and cooperative purchasing alliances. The recent solicitations under this code reveal a range of pharmaceutical procurement activities: state and local health departments are buying naloxone (opioid overdose reversal medication) and drug deactivation systems for community health programs; state health commissions are exploring direct-to-manufacturer prescription fulfillment models to bypass traditional pharmacy benefit managers; and multistate cooperative purchasing alliances are sourcing generic pharmaceuticals and over-the-counter products for distribution across participating jurisdictions. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participant states). Vendors responding to opportunities under this code must meet federal compliance requirements including FDA registration, Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and E-Verify employment verification; maintain specified insurance coverage levels; and, when applicable, work through authorized wholesalers and pharmacy benefit management channels.

Recent activity spans Florida, Texas, and the multistate Minnesota-led cooperative purchasing network (which includes Oregon). Representative solicitations include Seminole County, Florida's IFB60459723LAS (issued June 30, 2026, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) requesting vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers, with contract awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The code shows active procurement spanning community health programs, state-level pharmacy benefit innovation, and multistate cooperative sourcing.